SCHEMBL633368

SCHEMBL633368

CCCCCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.60
SLC6A3 Q01959 3/20 0.60
CHRNA1 P02708 1/20 0.60
CHRNG P07510 1/20 0.60
ITGA5 P08648 1/20 0.60
CHRNB1 P11230 1/20 0.60
CHRNB2 P17787 1/20 0.60
CHRNB4 P30926 1/20 0.60
SLC6A4 P31645 1/20 0.60
CHRNA3 P32297 1/20 0.60
CYP2C19 P33261 1/20 0.60
HRH1 P35367 1/20 0.60
CHRNA7 P36544 1/20 0.60
OPRK1 P41145 1/20 0.60
CHRNA4 P43681 1/20 0.60
CHRND Q07001 1/20 0.60
KCNH2 Q12809 1/20 0.60
ALDH1A1 P00352 2/20 0.59
BLM P54132 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769133 0.99 SLC6A2 (0.61) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL634045 0.96 SLC6A2 (0.61) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL769847 0.91 SLC6A2 (0.64) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL770048 0.85 SLC6A2 (0.68) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL340227 0.83 SLC6A2 (0.68) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL1686427 0.83 SLC6A2 (0.68) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL35211 0.83 SLC6A2 (0.68) SLC6A2SLC6A3CHRNA1CHRNGITGA5
Hydrochloric Acid SCHEMBL12497918 0.82 SLC6A2 (0.68) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL4874443 0.81 SLC6A2 (0.64) SLC6A2SLC6A3CHRNA1CHRNGITGA5
SCHEMBL13151517 0.81 SLC6A2 (0.68) SLC6A2SLC6A3CHRNA1CHRNGITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919841-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2021-02-16 US disclosed
US-10919841-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2021-02-16 US disclosed
US-20180215701-A1 MONOAMINE REUPTAKE INHIBITORS RES TRIANGLE INST (US) 2018-08-02 US disclosed
US-20180215701-A1 MONOAMINE REUPTAKE INHIBITORS RES TRIANGLE INST (US) 2018-08-02 US disclosed
US-9562001-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2017-02-07 US disclosed
US-9562001-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2017-02-07 US disclosed
US-20120071560-A1 MONOAMINE REUPTAKE INHIBITORS RESEARCH TRIANGLE INSTITUTE 2012-03-22 US disclosed
US-20120071560-A1 MONOAMINE REUPTAKE INHIBITORS RESEARCH TRIANGLE INSTITUTE 2012-03-22 US disclosed
EP-2419400-A1 MONOAMINE REUPTAKE INHIBITORS RESEARCH TRIANGLE INSTITUTE (US) 2012-02-22 EP disclosed
WO-2010121022-A1 MONOAMINE REUPTAKE INHIBITORS RESEARCH TRIANGLE INSTITUTE (US) 2010-10-21 WO disclosed
WO-2010121022-A1 MONOAMINE REUPTAKE INHIBITORS RESEARCH TRIANGLE INSTITUTE (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071560-A1 MONOAMINE REUPTAKE INHIBITORS SLC6A2, SLC6A4, SLC6A3 SLC6A2 1/4885SLC6A3 3/4885CHRNA1 186/4885
US-10919841-B2 Monoamine reuptake inhibitors SLC6A2, SLC6A4, SLC6A3 SLC6A2 1/4885SLC6A3 3/4885CHRNA1 186/4885
US-20180215701-A1 MONOAMINE REUPTAKE INHIBITORS SLC6A2, SLC6A4, SLC6A3 SLC6A2 1/4885SLC6A3 3/4885CHRNA1 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.